Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (27)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  3. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease

    Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167

  3. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

  4. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  3. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

    Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433

  4. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

    American Journal of Hematology

2021

  1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    Journal of Hematology and Oncology, Vol. 14, Núm. 1

  2. Seghi study: Defining the best surveillance strategy in hodgkin lymphoma after first-line treatment

    Cancers, Vol. 13, Núm. 10

  3. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Current functioning of cardio-oncology units in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1418-1422

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

  2. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

    Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620

  3. Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey

    Revista Espanola de Cardiologia, Vol. 72, Núm. 1, pp. 84-86

2018

  1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica